We evaluated patients with coronary artery disease and LDL-C < 130 mg/dl enrolled in the TNT ( Treating to New Targets ) trial , randomly assigned to receive atorvastatin 80 mg/day versus 10 mg/day and with at least one post-baseline measurement of LDL-C .